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Developing fibre optic Raman probes for applications in clinical 
spectroscopy 
Oliver Stevensa, Ingeborg E. Iping Petterson a,b, John Day a, Nick Stoneb,c 
Raman spectroscopy has been shown by various groups over the last two decades to have significant capability in 
discriminating disease states in bodily fluids, cells and tissues. Recent development in instrumentation, optics and 
manufacturing approaches has facilitated the design and demonstration of various novel in vivo probes, which have 
applicability for myriad of applications. This review focusses on key considerations and recommendations for application 
specific clinical Raman probe design and construction. Raman probes can be utilised as clinical tools able to provide rapid, 
non-invasive, real-time molecular analysis of disease specific changes in tissues. Clearly the target tissue location, the 
significiance of spectral changes with disease and the possible access routes to the region of interest will vary for each 
clinical application considered. This review provides insight into design and construction considerations, including suitable 
probe designs and manufacturing materials compatible with Raman spectroscopy. 
Introduction 
This review provides an overview of various clinical 
applications of Raman probes to date. This is followed by a 
discussion of key considerations for the design and use of 
biomedical Raman fibre probes for clinical application. There 
have been a number of recent review articles detailing various 
optical design options1,2, these are only briefly covered in this 
article. Here we focus predominantly on critical design 
considerations for optimising Raman probe performance for 
specific clinical applications.  
 
Raman spectroscopy 
Raman spectroscopy has been demonstrated by numerous 
research groups to be a powerful tool for molecular analysis of 
disease3,4,5. The technique relies upon the phenomenon of 
inelastic scattering of laser light by molecules in the sample 
volume 6. The shift in energy of the scattered light is specific to 
the vibrational modes of the molecules composing the cells 
and tissues of interest. As the technique relies upon light to 
probe disease specific molecular changes, it can be applied 
non-invasively, particularly where fibre optic access is possible.  
The molecular information obtained can be used for the 
discrimination of cell and tissue types, and diseased versus 
healthy tissues7. Raman spectroscopy based instruments have 
the potential to provide, rapid, objective, minimally-invasive 
tools for use in the clinic; that are able to provide 
discrimination that matches and even surpasses gold standard 
techniques8.  
 
Biochemical changes in cells and tissues are a result of 
epigenetic changes leading to a modified phenotypic 
expression of the cell. These changes can often precede a 
morphological changes used by pathologists for disease 
discrimination. Individual cells of similar origin, such as 
prostate cancer cells can be separated into cell line heritage 
and their associated susceptibility to androgen stimulus.9 
 
Identifying disease specific molecular changes using 
inelastically scattered light from cells and tissues often 
requires multivariate techniques, such as linear discriminant 
analysis, partial least squares discriminant analysis or support 
vector macjines.10,11 The changes observed are usually subtle 
variations in the relative concentrations of proteins, lipids, 
carbohydrates, nucleic acids and amino acids. Changes in 
protein conformations and lipid saturation can also be markers 
for disease states.  
 
Malignancy associated changes can also be probed using these 
techniques. Crow et al. showed bladder cancer surface 
measurements were indicative of the stage as well as grade of 
disease, ie the level of invasion into the surrounding organ as 
well as the cancerous nature if the individuals cells being 
probed.12 Leiber et al., showed in organotypic skin tissue raft 
cultures that Raman could distinguish the presence of sarcoma 
fibroblast cells in regions adjacent to the sampled volume, 
when compared to normal fibroblast cells.13 Furthermore, 
Singh et al. demonstrated malignancy associated changes in 
the buccal mucosa probed by Raman in at risk patient groups 
from tobacco exposure.14  
 
Although Raman has good chemical specificity, it is hindered 
by the low probability of an inelastic scattering event. From 
one million photons interacting with a molecule, there may 
only be one photon that is inelastically scattered. 
Furthermore, at visible illumination wavelengths many 
biomolecules exhibit fluorescence that can dominate the 
weaker Raman signal. This can be minimised by using near 
infrared (NIR) illumination, which is usually insufficient to 
induce electronic absorption. However, using longer 
wavelengths (λ) of light reduces the inelastic scattering cross-
section, which is proportional to λ-4. 
 
Accurately measuring these relatively small signals from 
biological tissues in vivo creates a technical challenge. Each 
application within the body imposes its own design constraints 
on the probe, to ensure optimum delivery of the excitation 
light and the efficient collection of the inelastically scattered 
light. This has led to the development of various different 
Raman spectroscopy-based probe instruments for in vivo use. 
In general, such probes must be relatively small, yet still 
provide spectra of sufficient quality in a reasonably short 
measurement time. Additionally, the probes must meet the 
specific requirements for in vivo clinical use such as being 
constructed of biocompatible, non-toxic materials and be 
sterilisable. In this paper we provide an overview of different 
probe design features as well as manufacturing processes that 
enable Raman probe instruments to be tailored to specific 
clinical / biomedical needs. Table 1 provides an overview of 
many of the Raman probes developed and utilised for 
biomedical applications to date. Key features of these probes 
will be discussed throughout this paper. 
 
Table 1: Summary of Raman probes and applications. 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Probe Main design features Medical Applications Citations 
Hollow Waveguides No fibres - minimised 
background 
N/A Miyagi and Kawakami, 198415 
Miyagi, 198516 
Komachi et al., 200517 
Komachi et al., 200518 
Optical fibre low background  Optimised probe for SERS to 
reduce Raman background 
N/A Ma and Li, 199419 
Ma and Li, 199620 
Envivia (Visionex) Inline filters in tip to reduce 
silica signal interference 
Measurement of various ex vivo 
tissues 
Shim and Wilson, 199721 
Shim et al., 199922 
Cervical probe Fibre optic bundle with inline 
filters (12mm diameter) 
Normal and precancerous 
cervical tissue in vivo  
Mahadevan-Jansen et al., 199823 
Optical fibre probe 1.75mm ball lens probe Normal and malignant breast 
tissue 
Motz et al, 200424 
Fibre optic array probe Spatially offset, circular array of 
fibres 
Measurement of bone spectra 
(rat and chicken) through skin 
M.V. Schulmerich, et al., 200625 
M.V.Schulmerich, et al., 200626 
Inverse SORS probe Illumination ring for minimal 
photo bleaching and depth 
measurements 
Deep Raman (subsurface) Matousek, 200627 
Micro Raman probe Micro Raman endoscope Rat Esophagus and Stomach in 
vivo 
Hattori et al., 200728 
Micro esophageal endoscope Confocal, sub-mm diameter Human Barrett’s oesophagus ex 
vivo, Oesophageal cancer  
Day et al., 200929 
Kendall, et al., 201030 
Almond, et al., 201231 
EMvision/ 
EMvision Miniprobe 
6 fibres for collection around 1 
for illumination. Filtration by 
coated fibres and lensing for 
beam steering. 
Human brain cancers in vivo 
(surgery); 
(rabbit) atherosclerotic 
plaque depositions in vivo; 
Lung cancer ex vivo 
Magee et al., 200932 
Matthäus et al, 201233 
Sharma et al., 201434 
J.Deroches et al., 201535 
Agenant et al., 201436 
M. Jermyn et al., 201537 
 SORS probe with multiple 
offsets 
Consecutive rows of collection 
fibres with SORS spacing from 
excitation fibre 
Human soft tissue layer 
discrimination and breast 
Tumour margins ex vivo 
Keller et al., 200938 
Keller et al., 201139 
High-axial resolution hollow 
waveguide probe 
Hollow waveguide with ball lens Stomach ex vivo (mice) Katagiri et al., 200940 
 
Contact fibre-optic probe Trans cutaneous measurements Trans cutaneous 
musculoskeletal tissues in 
human cadavers 
Esmonde-White et.al, 201041 
 Flexible silicone 360o  probe  Silicone band with plug-in 360o 
collection and excitation fibres 
(Mice)Bone in vivo, ex vivo 
 
Okagbare et al., 201042 
Beveled multi-fibre-tip probe 
 
Beveled with ball lens tip and in 
line filters 
Dysplasia in human Barrett’s 
oesophagus in vivo real time 
Bergholt et al., 201143 
Wang et al, 201344 
Bergholt et al., 201445 
Multicore fibre with integrated 
fibre Bragg gratings 
Potential to be semi-disposable 
Bragg gratings 
(Porcine) Brain tissue  ex vivo Dochow et al., 201246 
  
 
 
Clinical application of Raman probes 
Numerous groups have explored the use of Raman probes for 
clinical applications over the last 20 years. These have been 
explored for ex vivo point of care testing to in vivo analysis of 
superficial lesions such as skin and epithelial surfaces using 
endoscopic probes to in vivo analysis of tissues in open surgical 
field such as the breast and brain. A brief overview is given 
here to provide the context for the design considerations that 
follow.  
Intra-operative surgical applications 
Breast cancer surgery often requires intraoperative analysis of 
tissues to ensure clear tumour margins are removed and that 
any local invasion into surrounding lymph nodes is identified 
and treated appropriately. The feasibility of using Raman 
spectroscopy for intra-operative assessment of the sentinel 
axillary lymph nodes during breast cancer surgery has been 
explored58 Horsnell et al. utilised a commercially available 
portable spectrometer and large handheld probe MiniRam II 
(B&W Tek, Newark, DE, USA) to demonstrate the ability to 
discriminate normal and metastatic lymph nodes using 
multivariate classification models, achieving 85-92% sensitivity 
and 88-100% specificity in a leave-one-out cross-validation 
This device incorporates a 785nm laser with a spot size of 
85μm and a maximum power of 300mW at the probe tip.59 In 
this study only single points within the lymph nodes were 
probed. Minor improvements in sampling may improve results 
further. 
 
Raman spectroscopy has also been proposed for detection of 
tumour margins during breast cancer surgery, both in-vivo and 
ex-vivo.  
 
A hand-held Raman probe was developed for in-vivo collection 
of single-point Raman spectra during surgery.60 The authors 
measured 30 Raman spectra from nine patients: 29 from 
margins subsequently found to be negative on pathology 
examination (21 were composed of normal breast tissue 
whereas 8 contained fibrocystic change) and 1 spectrum from 
a margin subsequently found to be positive on pathology 
examination (high-grade ductal carcinoma in-situ). Although 
only one malignant sample was included, this study showed 
the potential for in-vivo diagnosis of margins during surgery. 
Alternatively, confirming negative resection margins can be 
achieved by analysing the surface of the resection specimen 
ex-vivo. 
 
Keller et al.38 performed a conceptual study applying spatially 
offset Raman spectroscopy (SORS)61 to the identification of 
soft tissue lesions ex vivo at depths of several mm’s. Further 
improvement of the SORS geometry in this application enabled 
sample characterisation up to depths of 2 mm.39 A probabilistic 
scheme was used to classify the composite spectra as 
‘negative’ or ‘positive’ margins. The discrimination achieved 
95% sensitivity and 100% specificity, when tested using a 
leave-one-out methodology. 
 
Photonic crystal fibre probe Kagome hollow core photonic 
crystal fibre, potentially 
disposable 
N/A Konorov et al. 200647 
P. Ghenuche et al., 201248 
Probe with polymer cap Built in calibration due to 
fluorocarbon probe tip 
Rat tibia Okagbare and Morris, 201249 
2-fibre subcutaneous needle 
probe 
Bevelled tip , inside hypodermic 
needle, sub-mm diameter 
Human lymph nodes ex vivo Day and Stone, 201350 
Kaiser PhAT probe Commercially available  
6 mm laser spot size for volume 
measurements 
Bone ex vivo 
Joint tissues 
Bone in vivo in surgery 
non-invasive through skin 
Esmonde-White and Morris, 201351 
Kosi.com52 
Endoscopic probe with shallow 
depth of field 
Ball lens for shallow depth of 
field 
In-vivo measurement of gastric 
dysplasia 
Huang et al. 201053 
Mo et al. 201054 
Hollow waveguide brain probe no fibres – Hollow needle Brain tissue ex vivo Stevens et al., 201455 
Iris- SORS probe adjustable SORS offset  proof of principle in phantoms 
and model systems 
Wang et al., 201456 
Multi-fibre needle probe Inside sub-mm hypodermic 
needle, disposable tip with non-
filtered distil fibre, autoclavable 
human lymph nodes ex vivo  Iping Petterson et al., 201557 
In the brain, Koljenovic et al. showed that fibre-optic Raman 
probes based on the high-wavenumber spectral region (2400 – 
3800 cm-1) can be used to characterise porcine brain tissue ex-
vivo.62 The measurement of the high-wavenumber spectral 
region avoids the background Raman scattering from silica 
fibres while still providing high-chemical specificity and 
diagnostic power.63,64 The authors developed multivariate 
classification model (least-squares fitting) that allowed 
discrimination of brain structures based on the biochemical 
contrast. The Raman spectra of gray matter was characterized 
by high intensity bands associated to proteins, DNA, and 
phosphatidylcholine compared with white matter, while the 
spectra of white matter was dominated by spectral features 
corresponding to cholesterol, sphingomyelin, and 
galactocerebroside.  
In vivo tissue analysis 
Preliminary work by Lieber et al using Raman spectroscopy on 
the skin, indicated high-diagnosis accuracy for non-melanoma 
skin cancers: 100% sensitivity and 91% specificity for 
discriminating tumours from normal skin.65 More recently, Lui 
et al developed an optimised hand-help Raman probe that 
allowed real-time (less than 1 second) in-vivo diagnostic.66 This 
large study (more than 1000 cases of skin cancers and other 
skin diseases) showed that it is possible to distinguish 
malignant and premalignant from benign lesions, melanomas 
from benign pigmented skin lesions, and melanomas from 
seborrheic keratoses, with sensitivities between 95% and 99%, 
although specificities range between 15% and 54%.66 
 
In 1998, Mahadevan-Jansen et al. published in vivo results 
using a fibre-optic Raman probe to analyse dysplastic change 
in cervical tissue.23 Silica-silica fibres were shown to cause less 
signal disruption than sapphire and liquid guide fibres despite 
their tendency to generate significant background signal at low 
wavenumbers (below 900 cm-1). The probe consisted of a 
single excitation fibre and 50 collection fibres and had a total 
diameter of 12 mm. The excitation fibre was positioned at the 
edge of the probe, and the laser output (at 789 nm) was 
reflected by a gold mirror at an angle to produce a 900 µm 
diameter excitation spot on the tissue surface. A bandpass 
filter on the distal tip of the excitation fibre blocked 
fluorescence and Raman scattering generated by the fibre, but 
transmitted the excitation light. Although demonstrating that 
Raman spectra could feasibly be measured in vivo using a 
fibre-optic, the dimensions of this probe and the time taken 
for spectral acquisition (90 s) meant this design was 
impractical for endoscopic use in other organs. 
Endoscopic diagnostic applications 
To enable access to other epithelial surfaces, where around 
80% of cancers originate, it is important to produce a 
miniature probe that is compatible for use with a medical 
endoscope. A gastric-endoscope is typically 90 cm in length 
with instrument channels of around 2.8 mm diameter, through 
which a Raman probe could be delivered. This presents a 
considerable technical challenge; to package a probe with all 
its constituent parts (filters, collimating lenses, illumination 
and collection channels, and external casing) into a durable 
device with a diameter smaller than 2.8mm. 
 
In 1999 Shim et. al. utilised an endoscope compatible, fibre-
optic Raman probe consisting of one central delivery fibre (400 
µm diameter) surrounded by seven collection fibres each with 
a 300µm diameter (Visionex probe).22 Filters were placed over 
the fibres approximately 2.5 cm from the probe tip and the 
collection fibres were part bevelled so that they 
predominantly collected signal from a zone in front of the 
delivery fibre and at a specified collection depth, determined 
by the bevelled angle. This design provided a means of 
controlling the sampling volume whilst optimising collection 
efficiency. 
 
In 2000, Shim et. al. reported the first in vivo Raman 
measurement of gastrointestinal tissue using the Visionex 
probe.67 In this feasibility study the probe was passed through 
an endoscope into the oesophagus, stomach and colon. 
Twenty patients successfully underwent the endoscopic 
procedure following routine sedation and no complications 
were reported. The probe was positioned to touch an area of 
mucosa for 5 seconds during which time readings were taken. 
The probed site was then biopsied to allow comparison of 
Raman spectra with histopathology at that site. Subtle 
differences were reported in spectra from normal and 
diseased areas but the data acquired was not sufficient to 
discriminate between pathological groups. Whilst 
demonstrating feasibility, Shim et al. concluded that more 
work was needed to enhance the SNR, to minimise acquisition 
times, and to improve data interpretation before reliable 
results could be generated. This study illustrated that 
endoscopic Raman spectroscopy could be performed safely in 
human patients, but was not large enough to enable 
comparison with results generated using laboratory based 
Raman spectrometers. 
 
Motz et al. used a novel probe to study dysplasia in rat palate 
tissue using 100mW of laser light (at 830 nm) for excitation.68 
Multivariate analysis demonstrated differences in low and high 
grade dysplasia, but it was concluded that further 
modifications to the probe were necessary to optimise 
collection depth as a significant spectral contribution was 
collected from tissue that was deeper than 500 µm. More 
recently a greater emphasis has been placed on targeted 
illumination of the epithelial lining of the gastrointestinal tract. 
Precancerous dysplasia develops in epithelial cells and, by 
definition, has not yet invaded deeper structures. For optimum 
diagnostic accuracy, probes must collect signal from the 
epithelial layer and minimise spectral contributions from 
scattering occurring in deeper tissues. 
 
In 2005, Wilson et. al. published results of an in vivo trial in the 
upper gastrointestinal tract of humans. They used a probe 
consisting of a central delivery fibre surrounded by six 300 µm 
  
diameter bevelled collection fibres that achieved an estimated 
sampling depth of 500 µm.69 In conjunction with a 785nm 
diode laser and an optimised spectrometer and CCD they 
reported an accuracy of 87% for delineating between normal 
oesophageal tissue and dysplasia. 
 
Day et. al. developed a confocal probe specifically designed for 
spectral measurement in the oesophagus.29 This probe 
consists of a single illumination and a single collection fibre 
with collimating graded index (GRIN) lenses to ensure optimal 
optical coupling, and in built filters to exclude intrinsic signal 
generated within the optical cables. The single fibre, which has 
a small aperture, shows a high degree of selectivity for 
detecting spectral signal arising from the epithelium. This 
probe was used to interrogate oesophageal biopsy tissue in 
vitro with 830nm light and demonstrated that Barrett’s 
oesophagus, dysplasia and cancer could be successfully 
separated with 71-88% sensitivity and 77-99% specificity.29  
In an attempt to achieve similar depth discrimination, Huang 
et. al. described the use of a ball lens at the distal tip of a novel 
Raman probe to focus excitation light onto the epithelium and 
help launch scattered light into the collection fibres.54  
 
Following a number of preliminary in vitro and in vivo studies 
in rats, Huang et al. published a series of results from in vivo 
trials of endoscopic Raman spectroscopy for the detection of 
gastric neoplasia in humans. They used a 1.8 mm diameter 
Raman probe consisting of 32 collection fibres surrounding a 
single central delivery fibre. The probe had two stages of 
optical filters, at its proximal and distal ends, and used 785 nm 
excitation. Each spectrum was acquired in 0.5 s with a laser 
light irradiance of 1.5 W/cm2. In 2010 they reported a 
diagnostic sensitivity of 82.1% and a specificity of 95.3% for 
delineating malignant gastric ulcers from benign tissue.70 In 
2011, the same Raman probe system was used in the 
oesophagus demonstrating a sensitivity of 97.0% and a 
specificity of 95.2% for detecting oesophageal cancer.43 
 
An in-house developed Raman probe was evaluated for ex-
vivo measurements on 105 colon specimens from either 
biopsies or partial colectomies (41 normal specimens, 18 
hyperplastic polyps and 46 adenocarcinomas) from 59 
patients.  With acquisition times of 5 seconds, the authors 
developed diagnostic algorithms that achieved a cross-
validated diagnostic accuracy around 98%, although this study 
did not include adenomas, which are an intermediate 
pathological group in the stepwise progression from normal 
tissue to adenocarcinomas.71  
Recently Sato et al. tested a miniature Raman-endoscope 
system was used to measure spectra sequentially over a 
period of several weeks to monitor tumour progression in 4 
mice with recognisable tumour lesions. Molecular changes in 
the tumour as it progressed, such as altered collagen type I 
and lipid content were measured and they were able to 
classify 86.8% of samples correctly as tumour versus normal 
tissue, when compared to histopathology.72  
Recent work by Short et al. has examined the possible use of 
high frequency Raman in the colon, measuring wavenumbers 
in the range 2050 to 3100 cm-1.73 Although discriminatory 
peaks were mostly detected at lower wavenumbers, 
measuring in this higher range reduces the effects of tissue 
auto-fluorescence and emissions in the fibre-optic probe itself. 
This means that cheaper probes can be produced without the 
need to filter the light within the probe. This small study in ex 
vivo fresh colonic tissue samples has shown that 
discrimination of pathology subtypes is possible using these 
higher wavenumbers with 1 second acquisition times. 
 
Much work in the oesophagus has been aimed at the 
development of a fibre-optic Raman probe for in vivo use, 
designed to be compatible with medical endoscopes. Initial 
work in rats models in-vitro showed potential for in vivo 
applications.74  Safety and feasibility of using Raman probes in 
the oesophagus was shown using an Enviva Visionex probe. 
400 spectra in 20 patients were measured using 5 second 
acquisition times, although discrimination of pathology was 
poor67 due to large sampling depths. This was followed up with 
a custom-built probe which was used to discriminate Barrett's, 
low-grade dysplasia (LGD) and high-grade dysplasia 
(HGD)/adenocarcinoma with accuracy 88%, 81% and 92% 
respectively in 192 spectra from 65 patients with Barrett's 
oesophagus using 5 second acquisition times.75  
Elsewhere, in vivo diagnosis of oesophageal cancer with 
Raman fibre-optic probes has been reported with sensitivity 
91% and specificity 94%, although subtype of cancer or 
degrees of dysplastic change were not differentiated. This 
study measured 263 oesophageal Raman spectra from 80 
patients (33 with cancer) with relatively fast acquisition times 
of 0.4–0.5 seconds.43,76  
 
Utilisation of a confocal Raman probe has been shown to 
provide accurate recognition of pathology subtypes using 
spectra acquired in 1 second using a Raman probe, giving 
sensitivities and specificities for normal squamous of 87% and 
96% respectively, Barrett's/LGD 72% and 91%, HGD/ 
adenocarcinoma 86% and 88%.77  
 
Seven hundred and ninety-eight, 1 second Raman probe 
spectra were acquired from 673 oesophageal tissue samples 
from 62 patients. 5 second and 0.1 second spectra were also 
recorded for comparison. Principal component fed linear 
discriminant analysis was used to calculate probe accuracy by 
reference to a consensus histopathological ‘gold standard’ 
diagnosis. All results were statistically cross validated, based 
on characteristic spectral signatures. High-grade dysplasia and 
adenocarcinoma could be discriminated from Barrett’s 
oesophagus, low-grade dysplasia and normal squamous 
oesophagus with a sensitivity of 86% and a specificity of 88%. 
The ability to detect early superficial mucosal disease, 
including discrimination between low-grade and high-grade 
dysplasia, was also demonstrated despite short, clinically 
applicable (1 second) spectral acquisition times. However, 
enhanced diagnostic accuracy was demonstrated when using 5 
s acquisition times; the detection rate of HGD/ 
adenocarcinoma remained 86%, but the specificity was greatly 
improved at 98%.77  
 
In addition, a potential algorithm for multi-system spectral 
classification was defined and consistent measurements were 
recorded by two independent operators using two identically 
built probes. The potential for bimodal diagnosis using a 
combination of RS and narrow band imaging was also 
demonstrated. No single incident of thermal tissue injury was 
reported.11  
 
The first use of Raman fibre probe based analysis in the blad- 
der was performed by Crow et al. using frozen tissues.78 A 
Visionex probe was used for this work at 785 nm and although 
the background signals from the probe were found to be 
significant there were still sufficient pathology specific signals 
to enable discrimination between 220 Raman spectra from 29 
snap-frozen bladder samples from benign (normal and cystitis) 
and malignant samples (transitional cell carcinoma), with an 
overall accuracy of 84%. However, the probe design required 
filters and expensive manufactured tips to minimise 
contributions from the signals induced in the fused silica core 
of the fibres. An alternative approach is to use the high wave 
number region (2400—3800 cm−1), where silica has no Raman 
signal. This enables the use of a single unfiltered fibre to guide 
laser light to the tissue and to collect scattered light in this 
spectral region. Koljenovi ́c et al. showed using in vitro Raman 
microspectroscopy on bladder tissue that both the fingerprint 
and high wavenumber regions contained similar levels of 
diagnostic information. Thus indicating simple fibre optics and 
the high wavenumber region may be sufficient for many 
applications.64  
 
The first in vivo bladder Raman studies using an Emvision 
probe based around a filtered six collection fibres around one 
illumination fibre.79 They used the fingerprint region and 
785nm illumination. The probes had no lenses or beam 
steering and this meant that signals were collected from both 
the urothelial surface of the bladder and the deeper layers, 
thus diluting the key diagnostic signals for early disease. 
Spectra were obtained from suspicious and non-suspicious 
bladder locations during the procedure of transurethral 
resection of bladder tumours (TURBT) with collection times of 
1—5 s. Multivariate analysis was used to generate the 
classification models. The algorithm was able to distinguish 
bladder cancer from normal bladder locations with a 
sensitivity of 85% and a specificity of 79%. The results show 
the possibility of discerning normal from malignant bladder 
tissue by means of Raman spectroscopy using a small fibre 
based system. Despite the low number of samples the results 
indicate that it might be possible to use this technique to 
grade identified bladder wall lesions during endoscopy. 
Integration into the clinical workflow 
 
Various attempts have been made to couple Raman with other 
modalities to maximise its potential for clinical impact. This 
section outlines a few examples.  
 
The feasibility of combining wide field imaging techniques with 
Raman probes for specific disease detection in the lung was 
investigated for pre-neoplastic lesions in-vivo, by integrating 
Raman spectroscopy measurements to a bronchoscope based 
on white light and autofluorescence.80 White light and 
autofluorescence images allowed identification of suspicious 
lesions, areas from which Raman spectra were measured with 
acquisition times of 1 second. The authors showed that 
sensitivity of 96% and a specificity of 91% for discrimination of 
pre-neoplastic lesions (leave-one-out cross validations) by 
developing multivariate statistical models. 
 
Fluorescence guided endoscopy (FGE) has been proposed as a 
guidance tool to improve early detection in diagnosis and 
complete removal of superficial transitional cell carcinoma 
during surgery. There is a great deal of evidence to 
demonstrate the benefits of the use of ALA-fluorescence 
cystoscopy for the identification of malignant lesions invisible 
at white light cystoscopy.81 The accumulation of PpIX, a 
precursor of heme, within abnormal cells enables these areas 
to be identified because they fluoresce red when illuminated 
with blue light. However several studies have demonstrated 
the low specificity of fluorescence imaging. Combining 
fluorescence with Raman spectroscopy in a multi-modal 
approach could improve its diagnostic capability. Optical 
biopsy by means of Raman spectroscopy at the region of 
interest selected by fluorescence imaging may enhance 
specificity and provide in vivo pathology.79,81 A major limitation 
in its clinical application is the weak nature of the Raman 
signal, which inhibits scanning large surface areas of tissues. 
 
In bladder cancer diagnosis, fluorescence-guided endoscopy 
with 5-aminolevulinic acid (5-ALA) has gained interest as a 
technique that can provide such spatial differentiation, thus 
improving early detection and more complete removal of 
superficial tumours. However, little is known about the effect 
of agents such as 5-ALA on Raman spectra of tissue. In samples 
with 5-ALA, an overall decrease in Raman intensity was 
observed when compared to the Raman spectra from samples 
without 5-ALA. Additionally, differences in relative intensities 
at 1270 and 1330cm−1 were also noted.81 However, significant 
differences were observed in the Raman spectra of benign and 
malignant samples with 5-ALA indicating the potential of using 
Raman spectroscopy for discriminating bladder cancer in the 
presence of 5-ALA.  
 
Another example of fluorescence-Raman diagnostics has been 
demonstrated in skin cancers.82 A more advanced system 
explored by Dochow et al., utilised a dual modality fibre optic 
probe combining fluorescence lifetime imaging (FLIm) and 
Raman spectroscopy for in vivo endoscopic applications. This 
was tested on various animal tissue samples and appeared to 
be able to provide signals from both modalitites to distinguish 
tissue types. There maybe some risks associated with the use 
  
of short wavelength excitation of the FLIm signals. A risk / 
benefit analysis may show this to be of overall benefit to the 
patient.83  
 
One further demonstration of real-world clinical translation 
has been demonstrated by Desroche et al.35 and Le Blond et 
al.36 They have integrated a neuro-navigation attachment on 
the probe to allow co-registration with preoperative MR 
images. A further advancement for prostate cancer surgery by 
Nyberg et al.84 have shown that Raman spectroscopic probes 
can be combined with tactile resonance approaches to provide 
surgeons with ‘feel’ and  biochemistry of prostate tissues. 
Key clinical Raman probe characteristics 
Size 
Small Raman probes are often desirable, as they enable new 
applications that cannot be addressed by larger probes. 
Miniaturisation comes with a cost however, particularly in 
terms of collection efficiency, and design options are far more 
limited at smaller sizes. The Raman probes demonstrated to 
date can be broadly separated into three size classes (Table 2). 
Table 2. Small fibre optic based probes have been designed for different 
medical applications.  
Probe 
diameter 
Application Design constraints Signal 
Performance 
cm Portable analysis 
outside body, 
e.g. skin 
Low, most optical 
designs possible 
Very high 
mm Endoscope: 
hollow organs 
Moderate, many 
optical designs 
possible but 
challenging 
High 
sub-mm Below skin, Solid 
organs 
Optical designs 
very limited, even 
basic lenses 
difficult to include 
Moderate 
 
 
The largest class of probe generally has diameters around the 
centimetre scale. Such probes are essentially handheld. There 
are a good number of commercially available probes at this 
size, there are few limits on the designs possible, and 
throughput and Raman collection performance is typically 
excellent. These probes can often achieve similar performance 
in terms of signal per mW per cm-1 as achieved with a 
microscope based system. These types of probes are usually 
used on skin, accessible organs, or exposed parts of the body 
during surgery.85 
At the millimetre scale construction becomes more difficult, 
especially if good optical alignment is required. Although 
bespoke commercial manufacture is becoming more widely 
available, most probes of this size range have been produced 
by research groups. Filters and lenses can be incorporated at 
this scale, but optical designs are significantly limited by space 
constraints. Probes within this size range are small enough to 
enter into the human body to inspect hollow organs, as they 
may fit into endoscopes, which have working channels 
generally of the order of 2-3 mm. Spectral performance can be 
very good, but is typically lower than that of larger probes and 
microscope based spectrometers. 
Sub-millimetre probes can be utilised to penetrate beneath 
the skin and into solid organs, either directly as a needle 
probe, or into a core biopsy needle. At this size range optical 
designs options are severely limited and incorporation of 
lenses and filters can be a challenge. 
Fibre optic probes 
Fibre optics provide many advantages for biomedical Raman 
probes because they act as a flexible waveguide, directing the 
excitation beam to the point of interest, and they also improve 
the efficiency of backscattered collection by returning more 
collected light back to the detector. 
 
Glass fibres 
Fibre optics used for Raman spectroscopy applications are 
most often multi-mode fibres formed of fused silica glass 
(SiO2) in a step-index format. The refractive index of the fibre 
core is made considerably higher than that of the cladding, by 
elemental doping of the silica glass, typically with elements 
like Fluorine, Boron or Titanium. This refractive index miss-
match causes total internal reflection within the fibre core, as 
depicted in Figure 1.  The light that enters the core is not able 
to escape laterally through the cladding and therefore is 
propagated through the fibre length. Generally, fibres are also 
encased in a buffer or external protective coating, made of 
metal or polymer that strengthens the fragile fibres. For 
biomedical applications utilizing NIR light, the use of low-OH 
silica glass is recommended to reduce OH absorption in this 
region of the spectrum.  
 
Figure 1. Schematic diagram showing total internal reflection in glass fibre optic. 
Maximising throughput 
The collection efficiency of a system is characterised by its 
étendue, which is the product of the collection area and the 
solid angle over which scattered light is collected by the 
system.  The concepts of étendue and the Lagrange Invariant 
must be born in mind when designing a system since an ideal 
optical design conserves étendue along the optical path. The 
system is therefore ultimately limited by the étendue of the 
least efficient component in the system. In small systems with 
small working distances this is usually governed by the optical 
fibres or ultimately by the spectrometer itself.  Spectrometers 
are typically specified by their f-number: defined as the ratio 
of the focal length to the diameter of the effective aperture of 
the entrance optics. Many typical Raman spectrometers have 
f-numbers of 2 or greater. For optical fibres the collection 
angle is usually specified as the Numerical Aperture (NA), 
which describes the illumination and collection cones 
produced or accepted by the fibre. NA is defined as the sine of 
the half angle of the collection cone. The NA of the fibres is 
determined by the refractive indices of the core (n1) and 
cladding (n2) of the fibre and given by  
 
Eq.1.      𝑁𝐴 =  √(𝑛1
2 + 𝑛2
2) 
 
Fibre optics are readily available with NA values ranging from 
0.1 to 0.5. NA. NA and f-number are related by the equation 
 
Eq. 2       f-number = 1/(2NA) 
  
The importance of the conservation of étendue can be shown 
by a simple example. A single fibre can be used for light 
collection at the sample and connected directly to the input 
aperture of a spectrometer. A large numerical aperture fibre is 
clearly preferable for the most efficient collection of light 
however a typical fibre has an N.A of 0.22 equivalent to an f-
number of 2.3. Many small spectrometers have f-numbers of 3 
or greater so the fibre is likely to overfill the acceptance angle 
of the spectrometer aperture and the spectrometer will not 
collect all of the light delivered by the fibre.  
The use of a high NA fibre is therefore unlikely to significantly 
increase the system throughput and is likely to create more 
stray light and background problems. Similarly the use of 
larger fibres is an intuitively obvious step to increasing light 
collection however the spectral resolution of the system is 
determined by the width of the spectrometer entrance slit. 
Typical Raman systems require slit widths of around 0.1 mm, 
similar to a typical fibre core diameter so larger cores may be 
vignetted by the slit and offer no advantage or may require a 
larger slit and result in a decreased spectral resolution. A 
larger fibre may be optically de-magnified onto the slit but the 
resulting angular magnification will create a larger effective 
numerical aperture so still overfilling the spectrometer.  
For these reasons it is usually preferable to increase the 
throughput by using multiple small fibres that can be arranged 
vertically along the slit width instead of a single large fibre. 
Some modern spectrometers are now available with entrance 
optics that asymmetrically image the source onto a virtual slit 
at the focal plane of the spectrometer so utilising the full 
available height of the entrance aperture and hence the 
maximum possible étendue of the spectrometer.86 Whatever 
configuration is used the étendue is still conserved and the 
overall system efficiency is always governed by the least 
efficient component.  
 
Fibre background 
Whilst there are clear advantages to the use of optical fibres in 
Raman probes, the silica that these fibres are constructed from 
impart an unwanted background signal onto the collected 
Raman spectrum. A Raman spectrum of a typical silica core 
fibre optic is shown in figure 2 This unwanted signal is 
generated in the laser delivery fibre and also by elastically 
scattered light entering the collection fibre.  
Qualitatively this has a detrimental effect on the spectrum, 
adding a significant background to the spectrum and causing 
the appearance to differ significantly from a spectrum 
collected by a Raman microscope, which hinders comparative 
analysis. It also has a quantitative effect on the signal to noise 
ratio, as the additional counts from the silica only serve to 
increase the total number of spectral counts and the 
associated noise with no beneficial effect.  
Reductions in silica background can have a marked effect on 
performance.  The scattered light measured exhibits shot noise 
described by Poisson statistics where the noise level increases 
as the square root of the number of incident photons. 
Equation 3 shows the expression for signal to noise taking into 
account the signal from the sample, NS, and the background 
signal from the silica, NB.  The detection limit of the desired 
signal is frequently determined by the shot noise present in 
the silica background instead of the collection efficiency of 
photons from the sample. This limit also becomes sample 
dependant as a highly reflective sample will reflect more of the 
excitation beam back through the probe and create a larger 
background. 
If the silica background is equal to twice the tissue Raman 
signal intensity, then the signal to noise ratio can 
approximately be doubled by removing the silica background 
altogether, or avoiding the spectral regions where the silica 
signals reside (see Figure 3).  
Eq.3                                        𝑆𝑁𝑅 =
𝑁𝑆 
√(𝑁𝑆+𝑁𝐵)
 
Figure 2: Raman Spectrum of Silica fibre. Note the characteristic background 
shape, particularly below 700cm-1 
  
 
Figure 3. Signal to noise ratio versus background for fixed signal counts (Ns) of 
1000.  
Reducing this internal silica background is therefore an 
important challenge for probe designers, and also an 
increasingly important avenue for improvements in 
performance of designs that otherwise have throughput 
limited by spectrometer efficiency. One common reduction 
strategy is to ensure optical filters are placed as close as 
possible to the sample, to limit the length of fibre where the 
backscattered laser light can generate Raman signals from the 
probe itself. For larger probes this is straightforward, for 
smaller probes this can require tiny filters, or even filters 
coated directly onto components. In general most fibre optic 
probes place filters at the tip to eliminate the fibre 
background. This does place constraints on the design of the 
probe, and also makes them more expensive, potentially too 
expensive for single patient use. Even with state of the art 
filters of optical density of 6 or more, significant background 
still remains present in the spectrum. This silica background 
has been shown experimentally to increase with numerical 
aperture, and the length of both the collection and laser 
delivery fibres, though fibres carrying laser light have a larger 
effect.87 
Background subtraction during post-measurement processing 
can improve the similarity of probe spectra to reference 
spectra from Raman microscopes. However, it can also 
introduce unwanted distortions and variability between 
spectra and most importantly does not improve the 
quantitative signal to noise performance. The shot noise 
introduced by the background cannot be subtracted with the 
overall background signal profile.  
Many groups working with Raman probes have prudently 
avoided unwanted interference by restricting their analysis to 
the higher wavenumber regions of the spectrum (2800-3700 
cm-1).63,88,89,90 Although the entire spectrum is affected, the 
silica background is most significant below around 700cm-1. 
Some potentially useful discriminatory information is lost in 
ignoring the spectral features in this lower region, however 
with a large amount of chemical information available in the 
bands from 700cm-1 to 1800cm-1, good analysis can take place 
despite the interference.  
An alternative method has been explored for filtering the 
elastically scattered laser line from the collection fibres and 
thus minimising the induction of background signal from 
fibres. This uses in-line fibre Bragg gratings (FBG) to 
reject/reflect the laser light in the collection path. A Raman 
probe was built consisting of one excitation fibre and six 
multicore single-mode fibers (19 cores) with inscribed FBGs as 
collection fibres.46 
 
Fibre Buffer Composition 
Silica glass fibre optics are coated with a protective outer 
coating called a buffer or jacket that serves to add extra 
support and strength to the delicate fibre. These buffers may 
be made of various different materials; polymers or metal 
coatings are the most common.  If a minimal total diameter of 
the fibres is a critical aspect of probe design, the buffers can 
be removed. Polymer coatings are easily removed with 
specialized fibre stripping tools, and this can be facilitated by 
soaking the fibres first in a solvent like acetone to loosen the 
buffer.  Metal buffers can be removed by chemical etching. In 
all cases it must be ensured that the buffer layer does not 
contribute to the signal. This is particularly important for 
fluorescent buffers such as polyimide in which case the probe 
design must ensure that the buffer is not directly in the signal 
or collection path.   
A dense, opaque coating on the fibres, such as a metal buffer, 
can provide an advantage in a probe where fibres are tightly 
packed. This coating will eliminate any cross-talk between 
adjacent fibres, however a buffer also increases the overall 
diameter of the fibres considerably, and additionally, care 
must be taken to use biomedically approved materials. Metal 
coatings of gold or stainless steel are recommended, however 
copper and aluminium alloys are common fibre buffer 
materials, which may not be biocompatible and must be used 
with caution in biomedical probes. 
The fibre diameter, as well as total number of fibres and their 
packing configuration are frequently important considerations 
in determining the overall diameter of probes employing 
multiple collection fibres. These factors become increasingly 
critical the smaller the desired probe design, particularly for 
probes in the sub-mm range. Typical cladding diameters range 
upwards from 0.125mm with larger core sizes obviously 
necessitating larger fibres.   
Additionally, claddings and buffers/jackets may contribute 
towards dead space (inactive area of the probe), which can be 
reduced considerably by stripping off the fibre buffer jacket, 
however the resultant bare fibre is extremely fragile and some 
additional mechanical protection will usually be required. 
 
Hollow waveguides 
An alternative strategy is to replace fibres with waveguides: 
hollow glass tubes internally-coated with metal mirrors. It has 
been shown15,16.17,91 that this does indeed result in a lower 
silica background, but much higher losses than silica fibres 
have been reported. The diameter of these waveguides is also 
considerably larger than most silica fibres (0.7-1mm). Some of 
the flexibility of glass fibres is also lost, and manufacture is 
more difficult. 
For larger diameters (approx. 1-2mm), it is possible to use a 
collimated beam of light in the distal section of the probe and 
in effect no waveguiding is required.55 This is in effect a mini-
stand off design and makes it possible to use hollow metal 
tubes / needles without the requirement for fibres or 
waveguides, improving medical compatibility. The lower 
numerical aperture of this arrangement is broadly 
compensated for by the larger collection area and reduced 
background, though the applications are more limited as the 
probe cannot be allowed to flex in the collimated section. 
Studies in our own lab indicate that this configuration has an 
efficiency of about 10% compared to a 0.22 NA low-OH fused 
silica fibre (105/125 core cladding). However the significantly 
reduced fibre background can give a similar signal to noise for 
some applications. Figure 4 demonstrates the effect on 
background caused by different probe geometries. The 
conventional microscope based Raman system clearly shows 
the smallest silica background as expected followed by a 
miniature stand off system55 with minimal fibre use.  A two-
fibre needle probe and a commercially available fibre probe 
show the largest silica background signals 
 
Photonic Crystal Fibres 
A relatively new development is the availability of photonic 
crystal fibres (PCFs). In this class of fibre, light is guided in an 
air core, rather than in silica. In theory this implies no silica 
background at all, and groups that have used these fibres 
show large reductions in background, 10 times when the 
excitation fibre is replaced47 and 100 times where PCFs are 
used for both excitation and collection.48 Throughput has been 
shown to be much better than with metal-coated waveguides. 
So far the only demonstrations have been of very simple probe 
designs. PCFs are becoming much more readily available but 
remain very expensive in comparison to silica fibres, and whilst 
they can be designed to operate at many wavelengths they 
have a much narrower range of wavelengths that they will 
accept than silica fibres, reducing the range of Raman shifts 
than can be observed when used for collection as well as 
excitation. They also present construction difficulties, with 
generally small core sizes and delicate internal core structures. 
 
 
Figure 4: Spectra demonstrating differing silica backgrounds of various probe 
configurations. 
Manufacturing materials 
Utzinger and Richard-Kortum gave an overview of different 
manufacturing materials for biomedical probes, and their 
biocompatibility in 20032. Since this overview, many new 
materials and manufacturing techniques have become 
available, particularly of note, the increasing availability of 
additive layer manufacturing, or ‘3D printers’, capable of 
printing in different kinds of plastics, as well as metals. See 
supplementary information. 
 
Fluorescence from other probe materials 
Aside from inherent fibre background, another major culprit in 
spectral background contribution is the glue used to fix fibres 
and optics into place. Many medical-grade glues that are used 
to construct clinical instruments are UV-cured epoxies. These 
glues are not suitable for the construction of clinical Raman 
probes because they contain a fluorescent photo-initiator used 
for hardening the glue. Transparent/colourless 2-part 
chemical- or heat- cured epoxies are recommended for Raman 
probe construction.  
Even if the glue is not directly in the excitation or collection 
path of the probe, it is possible for a small fluorescence 
contamination to completely overwhelm the Raman signal due 
to stray reflections, as shown in Figure 5.  
 
 
 
Figure 5: Raman spectra of various biomedical- approved glues.  Glues with spectra 
shown in panel A are UV- cured and contain a fluorescent photo-initiator for hardening, 
and the resulting cured glue is highly fluorescent and not appropriate for use in Raman 
probe designs (see supplementary information). Panel B shows spectra from 
biomedically-approved 2-part epoxies that are colourless/transparent.  Panel A uses 
0.1 s acquisitions, panel B uses 1 s acquisitions, both with the same power density 
(Raman microscopy). 
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Geometry and sampling volume 
With Raman scattered photons so scarce, a probe must collect 
as much light as possible for the best performance. It is 
important though to be mindful that the end goal is 
classification or analysis, and hence it is crucial to be careful 
that the collected light is from the diagnostically relevant 
region of the sample. Collecting more total light, but from the 
wrong region of a sample may reduce the clinical effectiveness 
of the probe. The geometry of a biomedical probe design 
should therefore be a major consideration, and tailored to the 
nature of the clinical application. The sampling volume of a 
probe may be varied by altering various design parameters, 
including fibre diameter, number of fibres, fibre NA, the angle 
of the probe face with respect to the optical axis, as well as 
through the addition of lenses or other optics at the probe tip.   
Where the fibres are used at the distal tip of a probe without 
additional optics the fibre ends may be shaped to optimise the 
desired overlap between the illumination and collection 
regions, which in turn will affect the sampling volume. If the 
angle of the fibre face slopes away from the illumination cone 
of an adjacent fibre, this changes the area of overlap between 
illumination and collection angles (Figure 6). The refractive 
index of the sample medium also plays a key role here.   
If the critical angle of total internal reflection between the 
fibre face and the medium is reached then the light will exit 
through the cylindrical side rather than the fibre face.92,2 For a 
silica fibre in air this angle is 43.3 degrees and in water this is 
66 degrees. For tissue this angle is around 69 degrees (for nglass 
= 1.5 and ntissue = 1.4). However, probes are not always fully 
submerged into tissue and an air gap can exist between the 
probe tip and sample surface. 
If the angle slopes towards the illumination cone this can 
create a smaller acceptance angle and thereby a shallower 
sampling into the medium.  A common probe design that 
utilizes this design feature is to create a beveled tip on the 
probe face, which significantly changes the angle of 
illumination and collection towards a shallower collection 
volume. See Figure 6. 
 
Depth selectivity 
A number of biomedical Raman designs incorporate some 
form of ‘depth selectivity’, as an attempt to minimise 
collection of light from deeper regions within the sample, or 
collecting relatively more light from shallower regions of a 
sample. See table 3. This is of great importance in some 
applications. Examples include, diagnostic tools for skin and for 
epithelial cancers on the lining of organs such as the bladder, 
colon and oesophagus, whereby the dysplastic cells of interest 
are often in a very thin surface layer on the inner surface of 
the oesophagus, and a surface measurement is required to 
probe the cells of interest 60.  
 
Bevelled tips 
The simplest method of achieving some depth selectivity is to 
use a bevelled tip of the distal fibres. This method is favoured 
for its simplicity and use in smaller probes where other options 
are limited. This approach has been implemented in a two-  
fibre design50 or as a ring of collection fibres around a central 
excitation fibre.94 An in-depth overview of the effect on fibre 
acceptance and exiting angle of different fibre face angles is 
provided by Utzinger and Richards-Kortum 2003.2 
 
Figure 6: Demonstration of effect of geometric fibre shaping on collection 
volumes. 
 
For diagnostic scenarios where deeper or bulk sampling of 
tissue is required on the scale of a few mm subsurface, a flat-
face probe design, with separate illumination and collection 
fibres, is likely to be most amenable. See section on subsurface 
probes. 
 
Ball lenses 
There have been various probe designs that have involved 
utilisation of a ball lens at the tip of the probe. This serves to 
change the excitation and collection optical paths of the 
probe, as well as to provide protection for the probe tip. 
Choice of an appropriate lens can control the sampling 
volume. Using a ball lens offers a further improvement in 
depth selection over a bevelled tip, but is more complex to 
manufacture. 
The ball lens also creates a distance between the fibres and 
the sample, often referred to as the sample-probe gap, which 
can be controlled by the size of the ball lens and provides a 
critical distance between the fibre faces and sample for 
obtaining maximum signal collection (see Figure 7).95   
  
Confocal probes 
The strongest depth selectivity is achieved with a true confocal 
optical layout. This produces extremely strong rejection of 
signals outside of the shallowest region of the sample, at some 
cost to total throughput. Construction of such probes is 
complex, as it requires very careful alignment of the 
components.29 Techniques such as utilisation of silicon v-
grooves and 3D printing of optical scaffold mounds for mm 
scale probes have been utilised to date. 
 
 
Figure 7: illustration of the basic geometries of a probe with a flat face, a 
bevelled tip and with a ball lens.  
Subsurface probes and applications 
In some biomedical diagnostic scenarios, the tissue target of 
interest is not easily accessible from outside the body or even 
via orifices and hollow organs, but requires measurements 
through solid tissues deeper within the body. 
  
Spatially Offset Raman Spectroscopy (SORS) Spatially Offset 
Raman Spectroscopy (SORS) can be implemented if deeper 
subsurface sampling is required (cm + scale), or if a 
surface/sub-surface differential signal measurement is 
required. This relies upon the phenomenon first identified by 
Matousek and Morris, that increasing the spatial separation of 
the illumination and collection points leads to average Raman 
signal collection from greater depths.96 This is ideal for non-
invasive probing deep into samples (for example beneath skin) 
without invasive penetration.39,61,96,97 Collection over such a 
large region of a sample has its cost however, with reduced 
signal to noise and a reduction in spatial resolution. 
The sampling depth in tissues increases by the order of 1 mm 
for every 2 mm of spatial offset between excitation and 
collection spots.39,96,98 In combination with this of course the 
volume of tissue sampled also increases and the depth 
resolution of the measurement decreases due to the diffuse 
scattering of light in tissues.  
Variants on the SORS design include inverse SORS,27 where the 
illumination is delivered in a diffuse ring offset from a central 
collection area. Inverse SORS provides bulk sampling, and in 
spreading excitation photons over a larger sample area 
potential photodamage of the sample is reduced.  
Some applications of SORS probes for large tissue volume 
sampling include the study of disease specific, bone tissue 
chemistry relating to various disorders and diseases and 
injury,99 as well as instruments that are under development for 
detection of breast cancer, prostate cancer.100,101,102 
In the investigation of tumour margins during surgery, it is also 
important to discriminate any buried tumour tissue beneath 
the surface of an apparently normal tissue margin.65,103 
 
 
 
 
Table 3. Sampling depth provided by different probe designs. 
 
Sampling 
depth 
(approx.) 
Designs Example 
references: 
10s-100s 
um 
Confocal 
Lensed tip 
Day et al. 29  
Huang et al. 53 
mm Lensed tip 
beveled tip  
flat face tip 
Jaillon et al. 95 
Hattori et al. 28 
Komachi et al. 91 
cm Large laser spot 
 
SORS 
Deep Raman 
Kaiser phat 
probe52 
Matousek et al. 96 
Buckley et al. 99 
Imaging probes 
Raman probes that collect spatial as well as spectral 
information are highly desirable for biomedical applications. 
This has been possible using Raman microscopes for some 
time.  
Building Raman probes with this capability is much more 
difficult. Most probes that have been demonstrated have 
fallen into two categories. The first is a multi-fibre version of a 
single point Raman probe. CCD based spectrometers can 
capture spectra from multiple channels at once, which allows 
an image to be constructed. This approach captures spectra 
comparable to single point Raman probes, but with very 
limited spatial resolution. 
Another approach is to use a coherent fibre bundle to capture 
information with a high spatial resolution, and use a 
wavelength selective filter instead of a spectrometer. This has 
been demonstrated with acousto-optical-tunable-filters 
(AOTFs)104 and liquid crystal tunable filters (LCTFs).105,106 Both 
approaches have very low spectral resolution, typically too low 
for effective use in discriminating subtle differences in 
pathology. LCTF filters can be constructed with sub-nm 
resolution, but such filters would be extremely expensive and 
have very low throughput. Acquisition times are also likely to 
be prohibitively long, as Raman signal must be collected 
consecutively from each band of interest.  
Choice of laser wavelength 
Near infrared wavelengths in the range 785-830nm have been 
demonstrated to be the optimum choice for minimising 
fluorescence backgrounds in biological tissues while still 
allowing the measurement of the Raman scattered signals with 
silicon CCD dectectors.107 
  
Dealing with biological contaminations 
A major consideration in the design of biomedical probes is in 
minimizing soiling of the probe from biological tissues and 
fluids, as well as preventing cross contamination in multiple 
uses for different patients.  Various strategies have been 
employed to deal with these issues. Most commonly, probes 
are built to be robust and are constructed of materials that can 
withstand cleaning, sterilizing and autoclaving. Another 
strategy is through the use of a disposable protective sheath. 
Considerations must be taken to use sheath materials that will 
not interfere with the Raman measurements.  
A real breakthrough would be achieved by the production of 
single-use probes. By far the greatest limitation in constructing 
disposable probes is the high cost of optical filters and 
assembly. The group of Popp has designed a probe using 
integrated fibre Bragg gratings and multiple multicore single 
mode fibres in the collection that could potentially be 
disposable, as these fibres can eventually be cheaply made 
without the requirement of relatively expensive additional 
optical filter components.46 Alternatively, our own research 
group has developed a probe of fused silica fibres inside of a 
single use hypodermic needle tip which connects to a reusable 
probe body where the expensive optics are located.50  
Perturbation factors 
External factors  
Sample/patient preparation 
Schleusener et al provides a comprehensive review of their 
study of the effects of different potential perturbation factors 
in a measurement with a biomedical Raman probe.108 They 
found that sample preparation was one of the biggest sources 
of variance in Raman measurements on the skin: factors like 
body hair, skin creams, and lotions had a significant effect on 
the resulting spectra.  
 
Ambient light 
Ambient light has a considerable influence on Raman spectra 
taken in the clinical environment. Standard fluorescent or 
luminescent bulbs contribute mercury emission lines or 
broadband light respectively, as significant artefacts in the 
Raman spectrum. Taking measurements in a clinic or during 
surgery in a completely dark environment is not always 
possible, so one way to overcome this is by using LED lights, 
which typically have a much smaller contribution to the near 
infrared spectral background.65,102 
 
Conclusions 
  
Raman spectroscopy has been demonstrated to be a powerful 
diagnostic platform technology. In vivo probes show great 
promise for clinical use, but important design considerations 
must be made for each possible biomedical application. Here 
we have outlined various methods whereby Raman probes can 
be tailored depending on the clinical need; particularly the 
accessibility of the tissues, the sample size and structure, 
required sampling depth, and significance of the difference in 
the Raman spectral signals between the sample groups of 
interest. 
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